These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1885 related articles for article (PubMed ID: 33941899)

  • 1. A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics.
    Si L; Bai H; Rodas M; Cao W; Oh CY; Jiang A; Moller R; Hoagland D; Oishi K; Horiuchi S; Uhl S; Blanco-Melo D; Albrecht RA; Liu WC; Jordan T; Nilsson-Payant BE; Golynker I; Frere J; Logue J; Haupt R; McGrath M; Weston S; Zhang T; Plebani R; Soong M; Nurani A; Kim SM; Zhu DY; Benam KH; Goyal G; Gilpin SE; Prantil-Baun R; Gygi SP; Powers RK; Carlson KE; Frieman M; tenOever BR; Ingber DE
    Nat Biomed Eng; 2021 Aug; 5(8):815-829. PubMed ID: 33941899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically Relevant Influenza Virus Evolution Reconstituted in a Human Lung Airway-on-a-Chip.
    Si L; Bai H; Oh CY; Jin L; Prantil-Baun R; Ingber DE
    Microbiol Spectr; 2021 Oct; 9(2):e0025721. PubMed ID: 34523991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
    Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
    Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
    Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2
    Good SS; Westover J; Jung KH; Zhou XJ; Moussa A; La Colla P; Collu G; Canard B; Sommadossi JP
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step.
    Chan SW; Shafi T; Ford RC
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.
    Milewska A; Chi Y; Szczepanski A; Barreto-Duran E; Dabrowska A; Botwina P; Obloza M; Liu K; Liu D; Guo X; Ge Y; Li J; Cui L; Ochman M; Urlik M; Rodziewicz-Motowidlo S; Zhu F; Szczubialka K; Nowakowska M; Pyrc K
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33219167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.
    Glebov OO
    FEBS J; 2020 Sep; 287(17):3664-3671. PubMed ID: 32428379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin.
    Du X; Zuo X; Meng F; Han C; Ouyang W; Han Y; Gu Y; Zhao X; Xu F; Qin FX
    Cell Prolif; 2021 Jan; 54(1):e12953. PubMed ID: 33211371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds.
    Schöler L; Le-Trilling VTK; Eilbrecht M; Mennerich D; Anastasiou OE; Krawczyk A; Herrmann A; Dittmer U; Trilling M
    Front Immunol; 2020; 11():573526. PubMed ID: 33162987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.
    Yousefi H; Mashouri L; Okpechi SC; Alahari N; Alahari SK
    Biochem Pharmacol; 2021 Jan; 183():114296. PubMed ID: 33191206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells.
    Ter Ellen BM; Dinesh Kumar N; Bouma EM; Troost B; van de Pol DPI; van der Ende-Metselaar HH; Apperloo L; van Gosliga D; van den Berge M; Nawijn MC; van der Voort PHJ; Moser J; Rodenhuis-Zybert IA; Smit JM
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
    Yang L; Pei RJ; Li H; Ma XN; Zhou Y; Zhu FH; He PL; Tang W; Zhang YC; Xiong J; Xiao SQ; Tong XK; Zhang B; Zuo JP
    Acta Pharmacol Sin; 2021 Aug; 42(8):1347-1353. PubMed ID: 33116249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.
    Ortega JT; Zambrano JL; Jastrzebska B; Liprandi F; Rangel HR; Pujol FH
    Intervirology; 2020; 63(1-6):2-9. PubMed ID: 33099545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
    Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L
    Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 95.